The BBB maintains the neural microenvironment by forming a tight barrier between the blood and the brain. The BBB is primarily formed by brain endothelial cells (BECs) lining the microvascular system ([@bib17]). BECs form a tight seal but also mediate selective transcellular transport of nutrients and other essential components into the brain, and efflux of potentially toxic metabolites from the brain ([@bib1]). Nonspecific transendothelial transport of soluble components (i.e., transport that is not mediated by specific transporters) across endothelia can occur along two routes: a transcellular route, which may be mediated by vesicular transport, and a paracellular route along a pathway between neighboring cells. Brain capillaries allow little nonspecific transendothelial transport since they exhibit only very low rates of fluid phase transcytosis, and the paracellular route between individual BECs is sealed by TJs that are much tighter than in peripheral microvessels. Hence, TJs are a critical determinant of the permeability properties of the BBB. Since many potentially beneficial drugs are inactive because they are unable to cross the BBB, much effort has been directed toward the understanding of TJs of BECs to identify molecular mechanisms that could be manipulated to enhance drug delivery across the BBB.

In this issue, Shoichiro Tsukita\'s group ([@bib12]) reports the identification of claudin-5 as a critical regulator of BEC permeability. They show that knockout of claudin-5 in mice resulted in leakage of tracers from the blood into the brain, although based on electron micrographs of ultrathin sections and immunofluorescence TJs still formed and appeared to be largely intact. Such mutant mice developed normally but died a few hours after birth, which may or may not have been due to the BBB defect. The absence of claudin-5 altered the junctional properties so that they functioned like a molecular sieve, allowing tracer diffusion in a size-selective manner, but it did not cause nonspecific leakage of plasma components into the brain. This was surprising for two reasons. First, claudin-5 had been believed to be the main structural transmembrane component of BEC TJs; hence, its absence was widely expected to result in evident defects in TJ assembly and a general breakdown of the junctional barrier. Second, the size-selective permeability properties in the absence of claudin-5 suggest that BECs have the capability to allow size-selective diffusion of tracers across TJs similar to many epithelial cells. This is an exciting observation since it suggests that it might be possible to manipulate BEC TJs in a manner that results in a transient selective increase in the permeability for small molecules, permitting small drugs to cross the BBB without complete disruption of the junctional barrier.

How might selective permeability be mediated and regulated? In principal, BEC TJs have a similar architecture to those of epithelial cells ([@bib7]; [@bib15]). TJs contain different types of transmembrane proteins, such as junctional adhesion molecules and the polytopic proteins occludin and claudins. These transmembrane components are linked via multiple adaptor proteins (i.e., proteins with multiple protein--protein interaction motifs such as the ZO or MAGI proteins) to the actin cytoskeleton and various signaling components, such as protein kinases and GTP-binding proteins. Claudins appear to be the main structural transmembrane proteins of TJs and are major components of the typical TJ-associated intramembrane strands seen in freeze-fracture replicas ([@bib15]). Since only two claudins are known to be expressed by BECs, claudin-5 and -12, it was unexpected that knockout of claudin-5 did not have a major effect on TJ morphology. However, it could be that the absence of claudin-5 was compensated by up-regulation of the expression of another claudin. Additionally, claudin-5 deficiency might cause minor morphological changes that can only be visualized by freeze-fracture EM. Nevertheless, removal or addition of a claudin in cells that express multiple claudin family members does not generally have drastic morphological consequences on TJs, suggesting that the absolute amount of available claudin protein is not a critical determinant of junction biogenesis.

Removal or addition of claudins generally does affect the permeability properties of TJs. Claudins have mainly been linked to selective ion permeability. A prominent example is claudin-16/paracellin-1, which is responsible for paracellular flux of Mg and Ca in the kidney and is mutated in patients with familial hypomagnesemia-hypercalciuria (i.e., renal Mg wasting) ([@bib13]). Therefore, it is thought that claudins form paracellular pores or channels that mediate selective ion permeability ([@bib2]; [@bib15]). According to this model, the types of claudins that constitute these channels determine their ion selectivity. On the other hand, removal or addition of a claudin in the skin resulted in dehydration and disruption of the epidermal barrier, suggesting that claudins do not only affect ion permeability ([@bib9]; [@bib16]).

Since removal of claudin-5 did not seem to inhibit junction formation and since it resulted in a size-selective increase in permeability, it is unlikely that this phenotype was caused by gaps in the BBB, but rather likely it was caused by the activation of a mechanism that mediates size-selective paracellular diffusion. Presently, we do not know how this works, but as proposed for epithelia, such a mechanism may involve a series of diffusion barriers that contain fluctuating pores or channels that are formed by other claudin family members and/or occludin ([@bib6]; [@bib5]; [@bib3]). The latter protein, occludin, is also a polytopic transmembrane protein like the claudins and is associated with epithelial and endothelial TJs ([@bib8]). Experiments with cultured epithelial cells demonstrated that occludin regulates size-selective paracellular diffusion of hydrophilic molecules ([@bib3]). In BECs, claudin-5 might normally associate with and inhibit such a diffusion system, and therefore its removal results in increased size-selective paracellular permeability.

How could such a permeation mechanism be exploited for the development of therapies to manipulate the BBB? The possibility suggested by [@bib12] is to target claudin-5. It might be possible to remove or inactivate claudin-5 temporarily from TJs of BECs using, for example, peptides that compete with its extracellular interactions. A similar approach was used to remove occludin from TJs in cultured epithelia ([@bib18]). An alternative tool is *Clostridium* perfringens enterotoxin, which binds and removes claudin-4 from epithelial TJs ([@bib14]). One could engineer derivatives of the enterotoxin that are specific for claudin-5 and could therefore be used to permeabilize endothelial TJs. It could be, however, that in vivo removal of a transmembrane protein has too drastic an effect on permeability to be used for drug delivery; therefore, one may have to think of ways to modulate the activity of junctional components involved in the regulation of permeability in a more subtle manner. One possibility is to target occludin: it has been proposed that phosphorylation of its regulatory COOH-terminal cytoplasmic domain regulates paracellular permeability of endothelia ([@bib10]). Alternatively, it might be simpler to manipulate one of the intracellular signaling components that regulate paracellular diffusion, such as the guanine nucleotide exchange factor GEF-H1, a recently identified TJ-associated activator of RhoA ([@bib4]; [@bib11]). Although more research is needed to develop and validate such reagents and therapies, the study by [@bib12] provides a significant advance toward a molecular understanding of the BBB and its regulation, and demonstrates that BBB permeability can be manipulated in a selective manner.
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